Compare GOGO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOGO | RCKT |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 277.7M |
| IPO Year | 2011 | 2014 |
| Metric | GOGO | RCKT |
|---|---|---|
| Price | $3.61 | $2.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $8.50 | ★ $8.58 |
| AVG Volume (30 Days) | ★ 2.9M | 1.8M |
| Earning Date | 11-06-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | 0.06 | ★ 0.66 |
| Revenue | ★ $910,491,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.11 | $915.60 |
| P/E Ratio | $59.25 | ★ $3.75 |
| Revenue Growth | ★ 104.74 | N/A |
| 52 Week Low | $1.96 | $2.17 |
| 52 Week High | $7.76 | $5.45 |
| Indicator | GOGO | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 48.28 |
| Support Level | $3.24 | $2.17 |
| Resistance Level | $3.90 | $2.73 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | 0.17 | 0.04 |
| Stochastic Oscillator | 72.32 | 63.00 |
Gogo Inc is a broadband connectivity service for the business aviation market. It provides a customizable suite of smart cabin systems for integrated connectivity, inflight entertainment, and voice solutions. It generates two types of revenue: service revenue consists of monthly subscription and usage fees paid by aircraft owners and operators for telecommunication, data, and in-flight entertainment services, and equipment revenue consists of proceeds from the sale of ATG and narrowband satellite connectivity equipment and is recognized when control of the equipment is transferred to OEMs and dealers, which generally occurs when the equipment is shipped. Geographically, it operates in United States; and International as well.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.